New Releases from NCBI BookshelfAtogepant (Qulipta): Indication: For the prevention of migraine in adults who have at least 4 migraine days per month: CADTH Reimbursement Recommendation [Internet].​Atogepant (Qulipta): Indication: For the prevention of migraine in adults who have at least 4 migraine days per month: CADTH Reimbursement Recommendation [Internet].

By /

CADTH recommends that atogepant (Qulipta) be reimbursed by public drug plans for the prevention of migraine if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top